Currently, among the potential pathological mechanisms and intervention strategies that have been proposed as promising AD treatments, tuning acetylation levels with HDAC inhibitors or HAT activators is highlighted and widely recognized by researchers [10], [14]. This evidence concerns the gene TMPRSS11D and Alzheimer disease.